Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.
Dilan A PatelJing XiJingqin LuoBilal HassanShana ThomasCynthia X MaJian L CampianPublished in: Breast cancer research and treatment (2019)
Post-treatment lymphopenia and NLR elevation can persist until 1 year after treatment completion. Both portend shorter survival for patients with TNBC. Our data support the use of ALC and NLR to identify high risk patients who may benefit from clinical trials rather than standard of care therapy.